Uvulopalatopharyngoplasty (UPPP) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Uvulopalatopharyngoplasty (UPPP) is the most commonly performed surgical procedure for obstructive sleep apnea (OSA) and is also used to treat severe socially disruptive snoring. First described by Fujita and colleagues in 1981, UPPP involves the surgical reduction and reshaping of soft tissue in the oropharynx — including the uvula, soft palate, and excess pharyngeal wall mucosa — to enlarge the upper airway and reduce the collapsibility that causes apnea and snoring during sleep.

OSA affects approximately 1 billion people worldwide and is characterised by repetitive partial or complete collapse of the upper airway during sleep, causing oxygen desaturation, sleep fragmentation, excessive daytime sleepiness, and cardiovascular complications including hypertension, atrial fibrillation, and increased risk of stroke. The diagnosis is confirmed by polysomnography (sleep study) or home sleep apnea testing, with severity graded by the apnea-hypopnea index (AHI): mild (5–14 events/hour), moderate (15–29/hour), and severe (≥30/hour).

While continuous positive airway pressure (CPAP) therapy remains the first-line treatment with AHI reduction exceeding 90% in adherent patients, a substantial proportion of patients are intolerant of or non-adherent to CPAP. UPPP provides an alternative for carefully selected patients — particularly those with retropalatal obstruction (Fujita Type I) and concomitant enlarged tonsils. The surgical success rate (defined as AHI reduction of ≥50% and AHI <20/hour) is approximately 50%, making patient selection critical.

The procedure is performed under general anaesthesia through the open mouth (transoral approach) without external incisions. Tonsillectomy is typically performed simultaneously when tonsils are present, significantly improving outcomes compared to UPPP alone.

UPPP is primarily indicated for the treatment of OSA and snoring arising from retropalatal upper airway obstruction.

• Obstructive sleep apnea (OSA), mild to severe: Particularly effective when obstruction is localised to the retropalatal segment (Fujita Type I). Drug-induced sleep endoscopy (DISE) or Mueller's manoeuvre during nasendoscopy is used to identify the site of collapse before surgery.
• Primary snoring and upper airway resistance syndrome (UARS): Patients with disruptive snoring without significant apnea may benefit from palatopharyngeal surgery, though the evidence base is stronger for OSA.
• OSA in patients intolerant of CPAP: Including patients with claustrophobia, pressure intolerance, skin irritation, significant nasal obstruction rendering CPAP ineffective, or those with lifestyle constraints incompatible with nightly CPAP use.
• OSA with retrognathia or micrognathia: Combined with mandibular advancement procedures as part of multi-level surgery protocols (Riley-Powell-Stanford protocol).

Fujita Classification of Obstruction Site

Pre-operative identification of the site of obstruction is essential for predicting UPPP outcomes:

• Type I (retropalatal): Obstruction at the level of the soft palate and tonsils. Best candidates for UPPP; success rates 50–80%.
• Type II (combined retropalatal and retrolingual): Obstruction at both palatal and tongue base levels. UPPP alone is insufficient; multi-level surgery required.
• Type III (retrolingual only): Obstruction at the tongue base or hypopharynx. UPPP is ineffective; tongue base procedures or maxillomandibular advancement (MMA) are required.

Careful patient selection is the most important determinant of UPPP success. Pre-operative evaluation is multidisciplinary, involving an ENT/sleep surgeon, sleep physician, and often a maxillofacial surgeon.

Essential Pre-Operative Investigations

• Polysomnography (PSG) or home sleep apnea testing (HSAT): Establishes diagnosis, baseline AHI, oxygen nadir, and sleep architecture.
• Drug-induced sleep endoscopy (DISE): Flexible nasendoscopy performed under light sedation (propofol or midazolam) to observe the dynamic site of airway collapse during induced sleep. Now considered essential by most sleep surgery guidelines to avoid performing UPPP in patients with tongue-base or multilevel obstruction.
• Cephalometry (lateral cephalometric X-ray): Assesses bony anatomy — posterior airway space, hyoid position, mandibular plane angle — relevant to surgical planning and predicting adjunct procedures needed.
• Nasal endoscopy: Assesses nasal anatomy for septal deviation, turbinate hypertrophy, or nasal polyps that may require concurrent correction.
• Tonsil and uvula assessment (Mallampati and Friedman staging): Larger tonsils (grades III–IV) predict better UPPP outcomes.

Ideal Candidate Profile

The best UPPP candidates have: Fujita Type I obstruction confirmed on DISE; prominent uvula with excess soft palate tissue; enlarged palatine tonsils (Friedman tonsil size II–IV); BMI below 30 kg/m²; and failed or intolerant CPAP trial. Patients with BMI above 35, severe OSA with multilevel collapse, or concurrent diabetes or cardiovascular instability require careful multidisciplinary assessment.

UPPP has evolved considerably since Fujita's original description, with several refinements and variants designed to improve outcomes and reduce complications.

1. Classic UPPP (Fujita Technique)

The original procedure involves tonsillectomy (if tonsils are present), excision of the uvula, trimming and repositioning of the soft palate margins, and removal of redundant lateral pharyngeal wall mucosa. The free edges of the anterior and posterior tonsillar pillars are sutured together to create a wider, more rigid oropharyngeal airway. Performed under general anaesthesia, typically 60–90 minutes.

2. Modified UPPP and Expansion Sphincter Pharyngoplasty (ESP)

Modifications aim to address lateral wall collapse more effectively. Expansion sphincter pharyngoplasty repositions the palatopharyngeus muscles superolaterally, tensioning the lateral pharyngeal walls rather than simply excising mucosa. Studies report success rates of 75–80% for Type I obstruction — significantly higher than classic UPPP in randomised comparisons.

3. Laser-Assisted Uvulopalatoplasty (LAUP)

An outpatient alternative to UPPP performed under local anaesthesia using a CO2 laser to progressively trim the uvula and soft palate over 3–5 sessions spaced 4–6 weeks apart. LAUP is primarily used for primary snoring and mild OSA; it is not recommended for moderate-to-severe OSA as it does not adequately address the pharyngeal walls. Avoids general anaesthesia but requires multiple visits and carries a risk of nasopharyngeal scarring with repeated sessions.

4. Radiofrequency Ablation of the Palate (Somnoplasty)

Radiofrequency energy delivered via a needle electrode creates submucosal thermal lesions that fibrose and stiffen the soft palate over 4–8 weeks. A minimally invasive, low-morbidity outpatient procedure effective for primary snoring and mild OSA. Multiple treatment sessions are typically required. Less effective than UPPP for moderate-to-severe OSA.

5. Multi-Level Surgery

For Type II and Type III obstruction, UPPP is combined with tongue base procedures (tongue base reduction, hyoid suspension, genioglossus advancement) as part of a staged or simultaneous multi-level protocol. Maxillomandibular advancement (MMA) — the most effective surgical treatment for OSA across all levels of obstruction — achieves AHI reduction of 80–90% at 5 years and is considered when simpler procedures have failed.

For appropriately selected patients with retropalatal obstruction, UPPP provides meaningful improvements in sleep quality, daytime function, and cardiovascular risk profile.

• AHI reduction without nightly device use: Successful UPPP reduces AHI by 50% or more in approximately half of carefully selected patients, providing durable benefit without the nightly compliance burden of CPAP.
• Snoring elimination: UPPP is highly effective for socially disruptive snoring — bed partners report elimination or major reduction of snoring in over 85% of cases regardless of AHI outcome.
• Improved sleep quality and daytime alertness: Patients with successful UPPP report significant reductions in Epworth Sleepiness Scale (ESS) scores, improved sleep efficiency, and better quality of life on validated instruments (FOSQ, SF-36).
• Cardiovascular risk reduction: Effective surgical treatment of OSA reduces nocturnal hypertension and may reduce the long-term risk of atrial fibrillation and stroke associated with untreated severe OSA.
• Permanent structural change: Unlike mandibular advancement devices (MAD) or CPAP, which must be used nightly, UPPP produces a permanent anatomical change in the airway that persists during sleep without any further device.
• One-time procedure: Unlike laser-assisted techniques (LAUP) requiring multiple outpatient sessions, UPPP achieves its maximal effect in a single procedure.

UPPP carries well-characterised risks that must be discussed in detail before consent. Complication rates vary with surgical experience and patient anatomy.

Early Post-Operative Complications

• Severe throat pain: The most common expected sequel, typically peaking at days 3–7. Managed with regular analgesia (NSAIDs, paracetamol, short-course opioids), cold liquids, and ice cream-based soft diet. Resolves completely by 2–3 weeks in most patients.
• Post-operative haemorrhage: Occurs in 2–5% of patients; primary bleeding (within 24 hours) or secondary bleeding (days 5–10 as eschar separates). May require return to theatre.
• Airway oedema: Transient post-operative pharyngeal oedema may worsen OSA in the first 48 hours; monitored with pulse oximetry, especially in severe OSA.
• Taste disturbance: Temporary altered taste sensation in approximately 10% of patients; typically resolves within 4–6 weeks.

Late Complications

• Velopharyngeal insufficiency (VPI): Nasal regurgitation of liquids and hypernasal speech due to inadequate soft palate closure. Occurs in 1–5%; usually mild and temporary. Severe persistent VPI is rare (<1%) and may require secondary surgical correction.
• Nasopharyngeal stenosis: Circumferential scarring causing airway narrowing, a rare but serious complication (0.5–1%) associated with excessive tissue removal or infection. Management is difficult and may require serial dilatations or surgical revision.
• Persistent or worsened OSA: Approximately 50% of UPPP patients do not achieve surgical cure by conventional criteria; some may have worsening of REM-specific or positional apnea post-operatively. All patients require repeat PSG 3–6 months post-operatively.
• Voice changes: Subtle changes in vocal resonance or pharyngeal sensation are uncommon but reported.

Recovery from UPPP involves a predictable 2–3 week period of throat pain and dietary modification. Post-operative surveillance is mandatory to assess surgical success.

First 48 Hours

Patients are admitted overnight for airway monitoring, particularly those with severe OSA or high BMI. Oxygen saturation is monitored continuously. Diet is restricted to cold liquids and soft foods. Analgesia is provided regularly around the clock; patients who used CPAP pre-operatively should continue using it post-operatively as the healing airway may be more obstructed than baseline in the first 2 weeks.

Weeks 1–3

Throat pain is significant and peaks around day 5–7. Regular analgesia, cool fluids, and ice cream are encouraged. Patients should avoid hard, crunchy, or spicy foods until healing is complete (approximately 3 weeks). Strenuous activity and alcohol should be avoided for 2 weeks. Most patients return to desk work after 1–2 weeks but may require 3 weeks before resuming physically demanding roles.

Post-Operative Assessment

A follow-up ENT review is arranged at 4–6 weeks to assess wound healing and document symptom change. A repeat diagnostic polysomnography is performed at 3–6 months post-operatively to objectively measure the change in AHI. This is essential: subjective improvement in snoring does not reliably indicate OSA resolution. Patients with residual moderate-to-severe OSA post-UPPP are counselled to resume CPAP or undergo evaluation for adjunct procedures.

UPPP costs reflect hospital, surgical, and anaesthetic fees, with significant international variation. The procedure is covered under many insurance plans when documented OSA is present and a CPAP failure trial has been conducted.

Typical Cost Ranges

• United States: USD 10,000–20,000 (hospital + surgeon + anaesthesia, pre-authorisation required; significant patient cost share after deductible)
• United Kingdom: GBP 4,000–8,000 (private sector; available on NHS with documented CPAP failure)
• India: USD 2,000–4,500 at accredited ENT centres
• Thailand: USD 3,000–6,500
• Turkey: USD 2,500–5,500
• Australia: AUD 6,000–12,000 (private, some Medicare rebate available)

Insurance and Documentation

Most insurers require: documented moderate-to-severe OSA by polysomnography; a trial of CPAP (typically 3 months) with documented intolerance or non-adherence; ENT or sleep physician recommendation; and in some jurisdictions, approval from a multidisciplinary sleep team. LAUP for primary snoring is typically not covered as it is considered elective.

Multiple evidence-based alternatives to UPPP exist. The optimal choice depends on OSA severity, site of obstruction, patient anatomy, BMI, and patient preference.

• Continuous positive airway pressure (CPAP): The gold-standard non-surgical treatment. Delivers positive airway pressure via a mask, pneumatically splinting the airway open. AHI reduction exceeds 90% in adherent users. Highly effective but requires nightly device use; adherence remains the primary limitation (~50–60% long-term adherence at 4 hours/night).
• Mandibular advancement device (MAD): A custom-fitted oral appliance that advances the mandible and tongue base during sleep, enlarging the retroglossal airway. Effective for mild-to-moderate OSA (AHI reduction 30–50%). Less effective than CPAP but better tolerated. Requires dental impression and specialist fitting.
• Palatal implants (Pillar procedure): Three braided polyester implants inserted into the soft palate under local anaesthesia to stiffen the soft palate and reduce flutter. Effective for primary snoring and mild OSA. Minimally invasive, reversible, and performed as an outpatient procedure. Not effective for moderate-to-severe OSA.
• Maxillomandibular advancement (MMA): Surgical advancement of both jaw bones, permanently enlarging the retroglossal and retropalatal airway. The most effective surgical treatment for OSA (AHI reduction 80–90%, comparable to CPAP). Indicated after failure of simpler procedures or as primary surgery in anatomically suitable patients with skeletal retrognathia. Major surgery requiring 4–6 weeks recovery.
• Hypoglossal nerve stimulation (HNS — Inspire device): An implantable device that synchronises electrical stimulation of the hypoglossal nerve with breathing, activating the genioglossus muscle and preventing tongue base collapse. FDA-approved for moderate-to-severe OSA in CPAP-intolerant patients without concentric palatal collapse. Success rates similar to or exceeding UPPP in properly selected patients (AHI reduction ~68%).
• Weight loss and bariatric surgery: Obesity is the strongest modifiable risk factor for OSA. A 10% reduction in body weight correlates with a 26% reduction in AHI. Bariatric surgery achieves sustained weight loss and significant OSA improvement in morbidly obese patients, and may eliminate OSA entirely in some cases.
• Positional therapy: For patients with predominantly supine OSA, avoidance of the supine position using positional devices (vibrating bands, positional pillows) reduces AHI by 50% or more. Simple, inexpensive, and effective in the appropriate phenotype.